VCRT | Hot Stock Picks

Having trouble reading this email View it in your browser.

Vicor Technologies, Inc.

VCRT Continues its Climb – Now Up 105% Since our Shareholder Vision Video Last Monday

Big Week Last Week for VCRT as it Moves Upward 88% from Monday Low to Friday Close – now up 105% and rising!

Monday saw a low of $0.085.

Today – so far – at: $0.175

See the video here: Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

To view the video interview, please visit: http://www.shareholdervision.com

June 21, 2011 – Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™ , an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicor’s PD2i Analyzer™ to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer™ as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer™ to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing. Sixty published manuscripts of studies involving the use of Vicor’s PD2i® nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit: http://www.shareholdervision.com

StockGuru`s Profile for Vicor Technologies, Inc. This is the condensed version – Full StockGuru Profile Found Here:

http://www.stockguru.com/about/vcrt/

Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i ® Algorithm and software. With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach. The Company has all of the regulatory approvals in place already with regards to PD2i ® to generate substantial revenues.

FDA Approval of PD2i Analyzer™ for BOTH Heart Rate Variability and Cardiovascular Disease Testing Vicor’s PD2i Analyzer™ has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics. And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer™ The potential market for the PD2i Analyzer™ with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer™ for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer™ as a valuable new diagnostic. The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i ® metric includes the classical Ewing maneuvers with the PD2i ® metric in patients undergoing cardiovascular disease testing. This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i ® technology by Vicor in 2003.

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents

PD2i ® Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing. Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists. Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications. Current procedural terminology (CPT) codes enable physicians using the PD2i ® Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

® Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

® Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i ® Algorithm New and Accurate Vital Sign

® Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i ® Algorithm:

First – the PD2i ® Analyzer Second - the PD2i Cardiac Analyzer ™ The PD2i VS ™ Vital Sign Monitor for trauma, triage, and other hospital uses in still under development.

FDA Clearance In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i ® nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

® Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i ® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.stockguru.com/about/vcrt/ Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com

Vicor Technologies North Bay Resources VIASPACE, Inc. Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNova About StockGuru: The original service that has become StockGuru started in the late `90`s. At first if was our publisher sharing picks with his friends. Then it grew. Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE . . Contact StockGuru: P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com

This message was intended for “ You have received this message because you are subscribed to `Stock Guru` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031. <a href="http://www.sgurunews.com/emailmarketer/

VCRT

Your email client cannot read this email.

To view it online, please go here:

http://www.sgurunews.com/emailmarketer/display.phpM596&C=c7c822f09eefcb0dac0453b7afd60b76&S49&L=3&N79 Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

Having trouble reading this email View it in your browser.

a Vicor Technologies, Inc.

Shareholder Vision Releases New Video Interview with David Fater of Vicor Technologies, Inc.

June 21, 2011 Dallas, Texas: John Pentony, Publisher of ShareholderVision.com, announced today that Shareholder Vision has released a new video interview featuring David Fater, President and Chief Executive Officer of Vicor Technologies, Inc. (OTCBB: VCRT). The interview was recorded recently in Boca Raton, Florida, the headquarters for Vicor Technologies, Inc. Shareholder Vision presents an exceptional look at an outstanding company, a CEO with world class experience in his field, and a bio-tech company that is now capitalizing on over a decade of patented work.

Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i nonlinear algorithm.

Physician use of the PD2i Analyzer is supported by an expanding body of literature documenting the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

Vicor is actively transforming itself from a development-stage biotechnology company into a fully-realized commercial venture with a national sales force and international distribution. Physicians are using Vicors PD2i Analyzer to identify autonomic nervous system, also known as diabetic autonomic neuropathy (DAN), in their patients with diabetes, and to identify those among their patients with cardiovascular disease at risk for death resulting from arrhythmia or congestive heart failure.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer as a measure of heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor. In April, Vicor received 510(k) marketing clearance from the U.S. Food and Drug Administration for its PD2i Analyzer to be used as a measure of heart rate variability at rest, and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Sixty published manuscripts of studies involving the use of Vicors PD2i nonlinear algorithm attest to its ability to identify and predict a wide variety of medical disorders and conditions.

To view the video interview, please visit:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L00&F=T Vicor Technologies, Inc. (OTCBB: VCRT) Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

Contact:

Shareholder Vision John Pentony, Publisher john@shareholdervision.com Tel: (469) 250-3030 StockGuru`s Profile for Vicor Technologies, Inc.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L69&F=T Vicor Technologies, Inc. (OTCBB: VCRT) is a medical diagnostics company focused on commercializing noninvasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i Algorithm and software.

With the second FDA approval under its belt in April, Vicor is fully in the process of transforming itself into a commercial company with a national sales force and international reach.

The Company has all of the regulatory approvals in place already with regards to PD2i to generate substantial revenues.

FDA Approval of PD2i Analyzer for BOTH Heart Rate Variability and Cardiovascular Disease Testing Vicors PD2i Analyzer has FDA 510(k) marketing clearance to both:

Measure heart rate variability (HRV) for physician-determined use which can assess autonomic nervous system dysfunction in diabetics.

And be used specifically in patients undergoing cardiovascular disease testing.

Potential Market PD2i Analyzer The potential market for the PD2i Analyzer with 77 million potential patients could be in the multi-billions of dollars. This market is supported by the recent FDA approval to market the PD2i Analyzer for cardiovascular disease testing is anticipated to spur market acceptance of the PD2i Analyzer as a valuable new diagnostic.

The groundbreaking 510(k) obtained in April of 2011, for the use of the PD2i metric includes the classical Ewing maneuvers with the PD2i metric in patients undergoing cardiovascular disease testing.

This FDA Approval is an accomplishment of incredible significance for VCRT as both national and international acceptance begin to accelerate. This landmark approval has been sought since the first introduction of the PD2i technology by Vicor in 2003.

These populations are significant:

23.6 million diabetics 15 million at-risk cardiac patients 38 million trauma incidents PD2i Analyzer Provides Additional Revenue Source for Physicians and Improves Patient Care Physicians can now expect a higher return on investment with the April 2011 FDA 501(k) for cardiovascular disease testing.

Vicor is now able to broaden its marketing message and could significantly increase interest in the Analyzer particularly with cardiologists.

Physicians are able to use the Analyzer for indications believed to be useful. FDA clearance of specific indications allows Vicor to explicitly market for those indications.

Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

The PD2i Analyzer is used as a diagnostic for heart rate variability, which is a widely-accepted measure of autonomic nervous system health and by extension cardiac health.

The PD2i Algorithm facilitates the ability of physicians to accurately risk stratify a specific target population to predict future pathological events such as autonomic nervous system dysfunction, cardiac mortality (either from arrhythmic death or congestive heart failure) and imminent death from trauma.

PD2i Algorithm New and Accurate Vital Sign The Company believes that the PD2i Algorithm represents a noninvasive monitoring technology that physicians and other members of the medical community can use as a new and accurate vital sign.

Two proprietary diagnostic medical products are being commercialized which employ software utilizing the PD2i Algorithm:

First – the PD2i Analyzer Second – the PD2i Cardiac Analyzer The PD2i VS Vital Sign Monitor for trauma, triage, and other hospital uses in still under development.

FDA Clearance In April 2011 the Company received 510(k) clearance from the U.S. Food and Drug Administration for its PD2i nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

Physician use of the PD2i Analyzer is supported by an expanding body of literature demonstrating the value of the PD2i nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events.

This is the condensed version – Full StockGuru Profile Found Here:

http://www.sgurunews.com/emailmarketer/link.phpM596&N49&L69&F=T Contact Vicor Technologies, Inc.

David H. Fater, CEO Vicor Technologies, Inc.

561.995.7313 dfater@vicortech.com ..

a Vicor Technologies North Bay Resources VIASPACE, Inc.

Vuzix Corporation Mantra Venture Group Princeton Security Technologies Next 1 Interactive AtheroNovaAbout StockGuru:

The original service that has become StockGuru started in the late `90`s.

At first if was our publisher sharing picks with his friends. Then it grew.

Then it became a formal list in 2001. In 2002 it became a web site. In 2003 it became StockGuru. READ ALL ABOUT IT HERE.

..

Contact StockGuru:

P: 469-358-5200 F: 214-975-1238 Publisher@StockGuru.com This message was intended for “ You have received this message because you are subscribed to `Bold Stocks Alerts` VCRT Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly. The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises LLC 1601 Berwick Drive McKinney, Texas 75070 (469) 252-3031.

VCRT

Having trouble reading this email View it in your browser.

Vicor Technologies, Inc.

Vicor Technologies` CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com

Company invites individual and institutional investors to view CEO David H. Fater`s presentation BOCA RATON, Fla., June 6, 2011 /PRNewswire via COMTEX/ — Vicor Technologies, Inc. (OTCBB: VCRT) today announced that CEO David H. Fater`s June 2nd RetailInvestorConferences.com presentation is now available for on-demand viewing. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer(TM), an innovative, non-invasive diagnostic used to risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. LINK: www.retailinvestorconferences.com > Click the red “register/watch event now” button. Mr. Fater`s presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the “virtual trade booth” for the next three weeks.

Vicor Technologies` PD2i Analyzer(TM) employs its patented, proprietary point correlation dimension algorithm (PD2i), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer(TM) to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.